An interventional study of Face-to-face exercise and Digital rehabilitation in Polycystic Ovarian Syndrome (PCOS), sponsored by Biruni University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Biruni University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Polycystic Ovary Syndrome with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Polycystic Ovary Syndrome · Turkey.
Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, this one is the 22nd largest by planned enrollment of the 29 interventional ones that give a count, is one of 12 that started in 2026, is one of 26 with no phase, reaches primary completion later than 9 of the 14 other live ones, and was the 62nd registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →14 of the 72 studies in Polycystic Ovary Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
Atlas University · Sites in Turkey
Ages 18–45 · Women only
Istanbul Health and Technology University · Sites in Turkey
Ages 18–40 · Women only · Healthy volunteers
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Ege University · Sites in Turkey
Ages 18–40 · Women only
Marmara University · Sites in Turkey
Ages 18+ · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 33 is below the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 54 across the 29 interventional studies, 90 across the 43 observational. Of the 50 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 72 has an industry lead sponsor. The 10 most frequent:
Biruni University is the lead sponsor of 183 studies on the registry; 45 are open to participants now.
Biruni University has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Polycystic Ovary Syndrome with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896642Istanbul Health and Technology UniversityBrown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography | 2026-12 |
| NCT07509762Biruni UniversityExercise Programs in Women With PCOS | 2027-01-15 |
| NCT07871851Inonu UniversityInvestigation of the Effectiveness of Spinal Stabilization Exercises Added to Aerobic Exercise in Women With Polycystic Ovary Syndrome | 2027-01-20 |
| NCT07342946Atlas UniversityThe Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome | 2027-04-01 |
| NCT07731373Kayseri City HospitalBiomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the effectiveness of a digital rehabilitation-supported combined exercise program in women with Polycystic Ovary Syndrome (PCOS). Participants aged 18-40 years will be randomly assigned to one of three groups: a digital rehabilitation group, a face-to-face exercise group, and a physical activity counseling group. The intervention will last 8 weeks, with exercise performed three times per week. Outcomes will include DNA methylation, hormonal and metabolic parameters, anthropometric measurements, body composition, muscle strength, basal metabolic rate, physical activity level, quality of life, menstrual cycle regularity, exercise adherence and satisfaction.
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder associated with metabolic, hormonal, and reproductive dysfunctions. Exercise is a key component in the management of PCOS; however, adherence to exercise programs remains a major challenge.
This randomized controlled trial aims to evaluate the effectiveness of a digital rehabilitation-supported combined exercise program compared to face-to-face supervised exercise and physical activity counseling.
Participants aged 18-40 years will be randomly assigned into three groups:
The face-to-face group will participate in supervised exercise sessions conducted by physiotherapist. The digital rehabilitation group will perform the same exercise protocol as the face-to-face group group online, live (synchronously), under the guidance of physiotherapist. The counseling group will receive physical activity recommendations.
Outcome measures will include epigenetic changes (DNA methylation), hormonal and metabolic parameters, anthropometric measurements, body composition, muscle strength, basal metabolic rate, physical activity level, quality of life, menstrual cycle regularity, exercise adherence and satisfaction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The presence of at least two of the following three criteria will be considered sufficient for a diagnosis of PCOS according to the Rotterdam criteria: (i) history of irregular menstruation with oligo/anovulation, (ii) clinical and/or biochemical signs of hyperandrogenism, (iii) detection of polycystic ovary images on ultrasonography.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will perform combined exercise sessions with a physiotherapist, three times per week for 8 weeks.
Behavioral: Face-to-face exercise
Participants will perform a combined exercise program by digital rehabilitation tools with physiotherapist, three times per week for 8 weeks.
Behavioral: Digital rehabilitation
Participants will receive physical activity recommendations.
Participants will perform the same combined exercise program (aerobic and resistance exercises) delivered in person by the study team. Sessions are supervised directly in a clinical setting.
Participants will perform a combined exercise program (aerobic and resistance exercises) through a digital rehabilitation platform.
Change in DNA methylation levels in women with PCOS
Genome-wide DNA methylation analysis will be used to measure methylation in blood samples taken baseline and after 8 weeks.
Time frame: Baseline and after 8 week
Hormonal Parameter Testosterone
Serum levels of testosterone will be measured at baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks.
Hormonal Parameter Luteinizing Hormone
Serum levels of luteinizing hormone (LH) will be measured at baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Hormonal Parameter Follicle-Stimulating Hormone
Serum levels of follicle-stimulating hormone (FSH) will be measured at baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Metabolic Parameter Fasting Blood Glucose
For the evaluation of fasting blood glucose (FPG) will be measured in all participants baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Metabolic Parameter Insulin Level
For the evaluation of insulin level will be measured in all participants baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Metabolic Parameter High-Density Lipoprotein Cholesterol
For the evaluation of high-density lipoprotein cholesterol (HDL-C) will be measured in all participants baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Metabolic Parameter Low-Density Lipoprotein Cholesterol
For the evaluation of low-density lipoprotein cholesterol (LDL-C) will be measured in all participants baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Metabolic Parameter Total Cholesterol
For the evaluation of total cholesterol will be measured in all participants baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Metabolic Parameter Triglycerides
For the evaluation of triglycerides will be measured in all participants baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Metabolic Parameter C-Reactive Protein
For the evaluation of C-reactive protein (CRP) will be measured in all participants baseline and after 8 weeks.
Time frame: Baseline and after 8 weeks
Anthropometric Measurements Waist Circumference
Waist circumference will be measured using standardized tape.
Time frame: Baseline and after 8 weeks
Anthropometric Measurements Hip Circumference
Hip circumference will be measured using standardized tape.
Time frame: Baseline and after 8 weeks
Body Composition Body Mass Index
Participants' BMI will be measured using Bioelectrical Impedance Analysis (BIA).
Time frame: Baseline and after 8 weeks
Body Composition Body Fat Mass
Participants' body fat mass (kg) will be measured using Bioelectrical Impedance Analysis (BIA).
Time frame: Baseline and after 8 weeks
Body Composition Body Fat Percentage
Participants' body fat percentage (%) will be measured using Bioelectrical Impedance Analysis (BIA).
Time frame: Baseline and after 8 weeks
Body Composition Body Muscle Percentage
Participants' body muscle percentage (%) will be measured using Bioelectrical Impedance Analysis (BIA).
Time frame: Baseline and after 8 weeks
Body Composition Body Muscle Mass
Participants' body muscle mass (kg) will be measured using Bioelectrical Impedance Analysis (BIA).
Time frame: Baseline and after 8 weeks
Body Composition Lean Body Mass
Participants' lean body mass (kg) will be measured using Bioelectrical Impedance Analysis (BIA).
Time frame: Baseine and after 8 weeks
Body Composition Visceral Fat
Participants' visceral fat will be measured using Bioelectrical Impedance Analysis (BIA).
Time frame: Baseline and after 8 weeks
Basal Metabolic Rate
Basal metabolic rate measurements will be taken using a portable indirect calorimeter.
Time frame: Baseline and 8 weeks
Peripheral Muscle Strength
Peripheral muscle strength assessment will include measurements of quadriceps femoris muscle strength and hand grip strength. An electronic hand dynamometer will be used to assess quadriceps femoris muscle strength. Participants' grip strength will be measured using a Jamar brand hydraulic hand dynamometer.
Time frame: Baseline and 8 weeks
Physical Activity Level
Physical activity level will be measured with a wearable activity monitor that tracks daily step count and activity minutes.
Time frame: Baseline and after 8 weeeks
Change in Quality of Life Score
The Turkish version of the Polycystic Ovary Syndrome (PCOS) Quality of Life-50 Questionnaire (PCOSQ-50) will be used to assess quality of life. The scale's total score and subscale scores are calculated using a scale with values of never 5, rarely 4, sometimes 3, frequently 4, and always 1. The total score ranges from 50 to 250 points.
Time frame: Baseline and after 8 weeks.
Change in Menstrual Cycle Regularity
Changes in menstrual cycle regularity will be assessed at baseline and after 8 weeks using daily logs.
Time frame: Baseline and after 8 weeks
Exercise Adherence
Participants' attendance and compliance with the sessions will be directly monitored by the physiotherapist. Attendance will be determined based on the number of sessions attended, for a total of 24 sessions. Attendance is defined as attending at least 80% of the scheduled exercise sessions.
Time frame: Baseline and after 8 weeks
Exercise Satisfaction
Participants' satisfaction level with the exercise programs will be assessed using the Global Rating of Change (GRC). Participants will be asked to express their level of satisfaction with the application using a single question. They will be asked to rate their satisfaction on a 5-point Likert scale, with "1" representing very poor satisfaction and "5" representing very good satisfaction.
Time frame: Baseline and after 8 weeks
Plan to share: No — Individual participant data (IPD) will not be shared due to privacy concerns and institutional regulations at Biruni University.
Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.
Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 4 months is below that.
Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.